The CAR-T Revolution: Side Effects, Results & What's Next | Tara Gregory, MD

Dr. Tara Gregory of the Colorado Blood Cancer Institute explains how CAR-T cell therapy works for relapsed and refractory multiple myeloma, from how T-cells are collected and engineered to target BCMA, to the most common side effects like cytokine release syndrome (CRS) and neurotoxicity. She walks through the clinical trial data behind the two currently approved CAR-T products, ide-cel (Abecma) and cilta-cel (Carvykti), including the KarMMa and CARTITUDE trials, why becoming MRD-negative may be a patient's first step toward a cure, and new research moving CAR-T earlier in treatment, even as a second-line therapy. She closes with what's coming next: a smaller, potentially less toxic BCMA-targeted CAR-T called anito-cel, a dual-target CAR-T called Durga, and emerging research on new targets like GPRC5D.